Phase 3 trial in 712 patients with resected stage III dMMR colon cancer: adding atezolizumab to mFOLFOX6 raised 3-year disease-free survival (86.3% vs 76.2%; HR 0.50, 95% CI 0.35–0.73); grade 3–4 adverse events 84.1% vs 71.9%.
RCTn = 712
Sinicrope et al. Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer